Clinical and histologic signs of regression two months after initiation of treatment with dabrafenib and trametinib in a case of stage IIIc BRAF V600E-positive scalp melanoma - 09/05/15
Erin Wei, MD, University of Miami Miller School of Medicine, Department of Dermatology and Cutaneous Surgery, Miami, FL, United States; Roberto Ruiz Cordero, MD, University of Miami Miller School of Medicine, Department of Pathology, Dermatopathology, Miami, FL, United States; Xiaolong (Alan) Zhou, MD, University of Miami Miller School of Medicine, Department of Dermatology and Cutaneous Surgery, Miami, FL, United States; Lynn Feun, MD, University of Miami, Miller School of Medicine, Department of Medicine-Hematology/Oncology, Miami, FL, United States; Giovanna Thomas, MD, University of Miami, Miller School of Medicine, Department of Otolaryngology, Miami, FL, United States; Jeong Hee Cho-Vega, MD, PhD, University of Miami, Miller School of Medicine, Department of Pathology, Dermatopathology, Miami, FL, United States
Le texte complet de cet article est disponible en PDF.| Commercial support: None identified. |
Vol 72 - N° 5S1
P. AB165 - mai 2015 Retour au numéro
Article précédent
- Characterization and assessment of nanoencapsulated sanguinarine chloride as a potential treatment for melanoma
- Clinical and histopathologic analysis of desmoplastic melanomas at a single institution
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?